top of page
Topic: Neuroendocrine tumours
CPGs graded Strong
Garcia-Carbonero, R., JImenez-Fonseca, P., Teulé, A. et al. (2014). SEOM clinical guidelines for the diagnosis and treatment of gastroenteropancreatic neuroendocrine neoplasms (GEP-NENs). DOI: 10.1007/s12094-014-1214-6 (Clin Transl Oncol (2014) 16:1025–1034). https://link.springer.com/content/pdf/10.1007%2Fs12094-014-1214-6.pdf
​
Aegerter P, Baujat B, Bensadoun RJ et al. (2017). Recommandation pour la Pratique Clinique : G3 - Tumeurs malignes primitives des voies aérodigestives supérieures en excluant le carcinome épidermoïde de type « commun». https://www.orlfrance.org/wp-content/uploads/2017/06/Refcor_VADS.pdf
​
Ramage JK, Ahmed A, Ardill J, et al. (2012). Guidelines for the management of gastroenteropancreatic neuroendocrine (including carcinoid) tumours (NETs). https://gut.bmj.com/content/gutjnl/61/1/6.full.pdf
​
Matysiak-Budnik T, Fabiani B, Hennequin C et al. (2018). Gastrointestinal lymphomas: French Intergroup clinical practice recommendations for diagnosis, treatment and follow-up. https://www.snfge.org/sites/default/files/SNFGE/TNCD/tncd_chap-10-lymphomes-gastrointestinaux_2017-12-21.pdf 
​
CPGs graded Moderate
Locher C, Batumona B, Afchain P, Carrère N A. et al. (2014). Small bowel adenocarcinoma: French Intergroup Clinical Practice Guidelines for diagnosis, treatments and follow-up. https://www.snfge.org/sites/default/files/SNFGE/TNCD/tncd_chap-13-adenocarcinome-intestin-grele_2017-09-15.pdf
​
Goichot B, Deblock M, Fein F et al. (2018). Tumeurs neuroendocrines du pancréas. http://oncologik.fr/referentiels/interregion/tumeurs-neuroendocrines-du-pancreas
​
Cadiot G, Baudin E, Couvelard A, Dromain C, Lepage C, LombardBohas  et al. (2017). «Tumeurs neuro-endocrines». Thésaurus National de Cancérologie Digestive, 03-2016. 
https://www.snfge.org/sites/default/files/SNFGE/TNCD/tncd_tne_version_finale_2016.pdf
​
Arpin D, Gérinière L, Lombard-Bohas C on behalf of the editing committee of Auvergne Rhône-Alpes Guidelines in Thoracic Oncology. [Guidelines on Chest Neuroendocrine Tumors: 2019 Update]. ARISTOT; 2019 [French]. ISBN 978-2-490858-09-5. Available from http://espacecancer.sante-ra.fr/Pages/referentiels.aspx and from www.lecancer.fr; http://referentiels-aristot.com/wp-content/uploads/5_TNE_2019_VDEF.pdf
​
Canlorbe G, Bendifallah S. (2015). Rare benign breast tumors including Abrikossoff tumor (granular cell tumor), erosive adenomatosis of the nipple, cytosteatonecrosis, fibromatosis (desmoid tumor), galactocele, hamartoma, hemangioma, lipoma, juvenile papillomatosis, pseudoangiomatous hyperplasia, and syringomatous adenoma: guidelines for clinical practice. J Gynecol Obstet Biol Reprod (Paris). 2015 Dec;44(10):1030-48. doi: 10.1016/j.jgyn.2015.09.034. Epub 2015 Oct 31.
​
Knigge U, Öberg K et al. (2012). Neuroendocrine gastro-entero-pancreatic tumors: ESMO Clinical Practice Guidelines for diagnosis, treatment and follow-up. Annals of oncology, 23 Suppl 7, vii124-30. doi:10.1093/annonc/mds295; https://academic.oup.com/annonc/article-pdf/23/suppl_7/vii124/6680258/mds295.pdf
​
Öberg, K., et al. (2012). "Neuroendocrine bronchial and thymic tumors: ESMO Clinical Practice Guidelines for diagnosis, treatment and follow-up." Annals of Oncology 23(suppl_7): vii120-vii123. https://academic.oup.com/annonc/article-pdf/23/suppl_7/vii120/6678716/mds267.pdf
​
Bozkurt MF, Virgolini I, Balogova S, et al (2017) Guideline for PET/CT imaging of neuroendocrine neoplasms with 68Ga- DOTA-conjugated somatostatin receptor targeting peptides and 18F-DOPA. Eur J Nucl Med Mol Imaging 44:1588–601. http://dskfnm.org/Doks/Guidelines/201701_EANM_NEN_GL_NationalReview.pdf
​
Caplin, M. E., et al. (2015). "Pulmonary neuroendocrine (carcinoid) tumors: European Neuroendocrine Tumor Society expert consensus and recommendations for best practice for typical and atypical pulmonary carcinoids." Annals of Oncology 26(8): 1604-1620. https://academic.oup.com/annonc/article/26/8/1604/247409
​
Unbenannt.JPG

Work Package 6

_project_management_standards.jpg

Tasks of work package 6

​

  • Map available clinical practice guidelines (CPGs) at the European level on all families of rare cancers and identify gaps

  • Quality evaluation of existing guidelines for rare cancer subtypes  

​

The JARC Work Package 6 maintains this website to share the results of quality evaluation of existing CPGs at European local and national level on rare cancers with partners involved in the EU JARC Project. However, the JARC Work Package 6 does not accept any responsibility or obligation of any kind whatsoever with regard to the information contained on this site.

The  JARC WP 6 Website contains links to other websites.

Not having control over the content of these third-party websites, no responsibility is assumed for their policies or practices.

Therefore, please review the privacy policies of these third-party websites.

Tasks of work package 6

​​

  • Open issues about implementation of CPGs at the local level and their interface with reimbursement systems

  • Work out solutions on how to assess the implementation of CPGs in the context of ERNs and national clinical collaborative networks

bottom of page